Luotea Oyj
17.3.2026 18:00:00 CET | Globenewswire | Press release
Transfer of Luotea Plc’s own shares
Transfer of Luotea Plc’s own shares
Luotea Plc
Stock exchange release
17 March 2026 at 7:00 p.m.
Transfer of Luotea Plc’s own shares
Luotea Plc has, based on the decision of the Extraordinary General Meeting held on 4 December 2025, transferred 5,943 shares to the members of the Board of Directors of Luotea Plc as part of the Board remuneration. This transfer relates to the remuneration of the board members who commenced their term on 31 December 2025.
The share transfer price is EUR 2,40 which is the volume weighted average quotation of the share on 12 March 2026. After the transfer, Luotea holds 560,960 of its own shares.
LUOTEA PLC
Heikki Eskola
General Counsel
More information
Heikki Eskola, tel. +358 50 586 5907
Luotea is a real estate service company that provides comprehensive solutions throughout the entire lifecycle of properties, integrating energy efficiency and data-driven technologies. Luotea’s services enhance property value and create the best possible conditions for property users. Our offering includes a wide range of advanced property maintenance, technical, and consulting services, as well as cleaning and support services.
Luotea operates in Finland and Sweden. In 2025, the company’s revenue totaled €346 million, and it employs approximately 5,000 people. Luotea is listed on Nasdaq Helsinki.
Distribution:
Nasdaq Helsinki
Media
www.luotea.com
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Orion Oyj24.10.2026 08:35:00 CEST | Press release
Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence
Zymeworks Inc.24.10.2026 08:30:00 CEST | Press release
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026
Junshi Biosciences24.10.2026 05:30:32 CEST | Press release
Junshi Biosciences Announces Completion of First Patient Dosing in the Phase 3 Clinical Trial of JS203 in Combination with Chemotherapy for the Treatment of Diffuse Large B-cell Lymphoma
SERB Pharmaceuticals23.10.2026 21:01:27 CEST | Press release
SERB Pharmaceuticals Announces Positive Results from the Post-Authorisation Efficacy Study of Idefirix® (imlifidase) Presented at ASN Kidney Week 2026
F. Hoffmann-La Roche Ltd23.10.2026 19:30:00 CEST | Press release
Roche presents interim phase III data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom